Cirugía de citorreducción en carcinomatosis peritoneal de origen gastrointestinal
DOI:
https://doi.org/10.35509/01239015.933Palabras clave:
carcinoma, peritoneo, neoplasias gastrointestinales, procedimientos quirúrgicos de citorreducción, quimioterapia intraperitoneal hipertérmicaResumen
La carcinomatosis peritoneal resulta del implante de las células malignas desprendidas de un tumor primario en el peritoneo, y son las neoplasias de origen gastrointestinal las que con mayor frecuencia presentan este compromiso. Inicialmente, fue considerada una patología terminal que situaba al paciente en un escenario de manejo paliativo con quimioterapia sistémica; sin embargo, durante el último siglo, el estudio de la enfermedad peritoneal ha cambiado el paradigma del enfoque en este grupo de pacientes, al aparecer la cirugía de citorreducción y la quimioterapia hipertérmica intraperitoneal como opciones terapéuticas factibles y seguras. Actualmente, se considera que el conocimiento y entrenamiento en este procedimiento, asociado a la selección adecuada de pacientes a cargo de un grupo multidisciplinario en centros de referencia, son la clave para lograr los desenlaces y el beneficio para los pacientes.
Biografía del autor/a
Silvia Guerrero-Macías, Fellow, Posgrado Médico-Quirúrgico de Cirugía Oncológica, Convenio Universidad Militar Nueva Granada - Instituto Nacional de Cancerología, Bogotá, D. C., Colombia.
1. Fellow, Posgrado Médico-Quirúrgico de Cirugía Oncológica, Convenio Universidad Militar Nueva Granada - Instituto Nacional de Cancerología, Bogotá, D. C., Colombia.
Ada Bustos-Guerrero, Residente, Cirugía General, Universidad Industrial de Santander, Bucaramanga, Colombia.
2. Residente, Cirugía General, Universidad Industrial de Santander, Bucaramanga, Colombia.
Alfonso Márquez-Ustariz, Fellow, Posgrado Médico-Quirúrgico de Cirugía Oncológica, Convenio Universidad Militar Nueva Granada - Instituto Nacional de Cancerología, Bogotá, D. C., Colombia.
1. Fellow, Posgrado Médico-Quirúrgico de Cirugía Oncológica, Convenio Universidad Militar Nueva Granada - Instituto Nacional de Cancerología, Bogotá, D. C., Colombia.
Rodrigo Burgos-Sánchez, Fellow, Posgrado Médico-Quirúrgico de Cirugía Oncológica, Convenio Universidad Militar Nueva Granada - Instituto Nacional de Cancerología, Bogotá, D. C., Colombia.
1. Fellow, Posgrado Médico-Quirúrgico de Cirugía Oncológica, Convenio Universidad Militar Nueva Granada - Instituto Nacional de Cancerología, Bogotá, D. C., Colombia.
Jorge Campillo-Pardo, Fellow, Posgrado Médico-Quirúrgico de Cirugía Oncológica, Convenio Universidad Militar Nueva Granada - Instituto Nacional de Cancerología, Bogotá, D. C., Colombia.
1. Fellow, Posgrado Médico-Quirúrgico de Cirugía Oncológica, Convenio Universidad Militar Nueva Granada - Instituto Nacional de Cancerología, Bogotá, D. C., Colombia.
Raúl Eduardo Pinilla-Morales, Unidad Funcional Gastroenterología, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia.
3. Unidad Funcional Gastroenterología, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia.
4. Docente, Universidad Nacional de Colombia, Bogotá, D. C., Colombia.
Mario Abadía-Díaz, Unidad Funcional Gastroenterología, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia.
3. Unidad Funcional Gastroenterología, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia.
Mauricio García Mora, Unidad Funcional Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia.
5. Unidad Funcional Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia.
Referencias bibliográficas
González D, Ruso L, Telles L. Carcinomatosis peritoneal. Conceptos y tratamiento con cirugía y quimioterapia hipertérmica intraperitoneal [Internet]. 2014. Montevideo: Ediciones Universitarias. Disponible en: https://www.csic.edu.uy/sites/csic/files/publicacion5b896f10a2d893.11912421.pdf
Brücher BL, Piso P, Verwaal V, Esquivel J, Derraco M, Yonemura Y, et al. Peritoneal carcinomatosis: Cytoreductive surgery and HIPEC-overview and basics. Cancer Invest. 2012;30(3):209-24. https://doi.org/10.3109/07357907.2012.654871
Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221(1):29-42. https://doi.org/10.1097/00000658-199501000-00004
Beaujard AC, Glehen O, Caillot JL, Francois Y, Bienvenu J, Panteix G, et al. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer. 2000;88(11):2512-9. https://doi.org/10.1002/1097-0142(20000601)88:11%3C2512::aid-cncr12%3E3.0.co;2-j
Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: A phase II study. J Clin Oncol. 2003;21(5):799-806. https://doi.org/10.1200/JCO.2003.06.139
Nissan A, Stojadinovic A, Garofalo A, Esquivel J, Piso P. Evidence-based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future. J Surg Oncol. 2009;100(4):335-44. https://doi.org/10.1002/jso.21323
Sampson JA. Implantation peritoneal carcinomatosis of ovarian origin. Am J Pathol. 1931;7(5):423-43. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062808/
Yonemura Y, Kawamura T, Bandou E, Tsukiyama G, Endou Y, Miura M. The natural history of free cancer cells in the peritoneal cavity. Recent Results Cancer Res. 2007;169:11-23. https://doi.org/10.1007/978-3-540-30760-0_2
Cortés-Guiral D, Hübner M, Alyami M, Bhatt A, Ceelen W, Glehen O, et al. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers. 2021;7(91). https://doi.org/10.1038/s41572-021-00326-6
Guerrero-Macías S, Briceño-Morales C, Puerto AP, Garcia-Mora M. Laparoscopic staging in patients with peritoneal carcinomatosis. An approach from cytoreductive surgery. Rev Colomb Cir. 2022;37(4):665-72. https://doi.org/10.30944/20117582.1578
Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Cancer Treat Res. 1996;82:79-100. https://doi.org/10.1007/978-1-4613-1247-5_6
Ben-Yaacov A, Dux J, Nissan A. Diagnostic laparoscopy for the evaluation of peritoneal metastases. En: Bhatt A, editor. Management of peritoneal metastases - cytoreductive surgery, HIPEC and beyond. Springer; 2018. Disponible en: https://www.researchgate.net/publication/324158725_Diagnostic_Laparoscopy_for_the_Evaluation_of_Peritoneal_Metastases/citation/download
Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: Mechanisms of the patterns of spread. Cancer Metastasis Rev. 2003;22(4):465-72. https://doi.org/10.1023/a:1023791229361
Los G, Mutsaers PHA, Lenglet WJM, Baldew GS, McVie JG. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol. 1990;25(6):389-94. https://doi.org/10.1007/BF00686048
Los G, Verdegaal EME, Mutsaers PHA, McVie JG. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991;28:159-65. https://doi.org/10.1007/BF00685503
Terzi C, Arslan NC, Canda AE. Peritoneal carcinomatosis of gastrointestinal tumors: Where are we now? World J Gastroenterol. 2014;20(39):14371-80. https://doi.org/10.3748/wjg.v20.i39.14371
Sugarbaker PH. Surgical responsibilities in the management of peritoneal carcinomatosis. J Surg Oncol. 2010;101(8):713-24. https://doi.org/10.1002/jso.21484
Grotz TE, Fournier KF, Mansfield PF. Patient selection for cytoreductive surgery. Surg Oncol Clin N Am. 2018;27(3):443-62. https://doi.org/10.1016/j.soc.2018.02.012
Goéré D, Souadka A, Faron M, Cloutier AS, Viana B, Honoré C, et al. Extent of colorectal peritoneal carcinomatosis: Attempt to define a threshold above which HIPEC does not offer survival benefit: A comparative study. Ann Surg Oncol. 2015;22(9):2958-64. https://doi.org/10.1245/s10434-015-4387-5
Mehta SS, Bhatt A, Glehen O. Cytoreductive surgery and peritonectomy procedures. Indian J Surg Oncol. 2016;7(2):139-51. https://doi.org/10.1007/s13193-016-0505-5
Elias D, Gilly F, Boutitie F, Bereder JM, Mansvelt B, Lorimier G, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63-8. https://doi.org/10.1200/JCO.2009.23.9285
Leimkühler M, De Haas RJ, Pol VEH, Hemmer PHJ, Been LB, van Ginkel RJ, et al. Adding diagnostic laparoscopy to computed tomography for the evaluation of peritoneal metastases in patients with colorectal cancer: A retrospective cohort study. Surg Oncol. 2020;33:135-40. https://doi.org/10.1016/j.suronc.2020.02.010
Jacquet P, Jelinek JS, Steves MA, Sugarbaker PH. Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer. 1993;72(5):1631-6. https://doi.org/10.1002/1097-0142(19930901)72:5%3C1631::aid-cncr2820720523%3E3.0.co;2-i
Seshadri RA, Raj EH. Diagnostic laparoscopy in the pre-operative assessment of patients undergoing cytoreductive surgery and HIPEC for peritoneal surface malignancies. Indian J Surg Oncol. 2016;7(2):230-5. https://doi.org/10.1007/s13193-015-0486-9
Rivard JD, Temple WJ, McConnell YJ, Sultan H, Mack LA. Preoperative computed tomography does not predict resectability in peritoneal carcinomatosis. Am J Surg. 2014;207(5):760-4. https://doi.org/10.1016/j.amjsurg.2013.12.024
Berthelot C, Morel O, Girault S, Verrièle V, Poirier AL, Moroch J, et al. Use of FDG-PET/CT for peritoneal carcinomatosis before hyperthermic intraperitoneal chemotherapy. Nucl Med Commun. 2011;32(1):23-9. https://doi.org/10.1097/MNM.0b013e328340e730
Elekonawo FMK, Starremans B, Laurens ST, Bremers AJA, de Wilt JHW, Heijmen L, et al. Can [18F] F-FDG PET/CT be used to assess the pre-operative extent of peritoneal carcinomatosis in patients with colorectal cancer? Abdom Radiol. 2020;45(2):301-6. https://doi.org/10.1007/s00261-019-02268-w
Suzuki A, Kawano T, Takahashi N, Lee J, Nakagami Y, Miyagi E, et al. Value of 18F-FDG PET in the detection of peritoneal carcinomatosis. Eur J Nucl Med Mol Imaging. 2004;31(10):1413-20. https://doi.org/10.1007/s00259-004-1577-y
Tanaka T, Kawai Y, Kanai M, Taki Y, Nakamoto Y, Takabayashi A. Usefulness of FDG-positron emission tomography in diagnosing peritoneal recurrence of colorectal cancer. Am J Surg. 2002;184(5):433-6. https://doi.org/10.1016/s0002-9610(02)01004-8
Fujii S, Matsusue E, Kanasaki Y, Kanamori Y, Nakanishi J, Sugihara S, et al. Detection of peritoneal dissemination in gynecological malignancy: Evaluation by diffusion-weighted MR imaging. Eur Radiol. 2008;18(1):18-23. https://doi.org/10.1007/s00330-007-0732-9
Low RN, Barone RM, Lucero J. Comparison of MRI and CT for predicting the peritoneal cancer index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2015;22(5):1708-15. https://doi.org/10.1245/s10434-014-4041-7
van 't Sant I, van Eden WJ, Engbersen MP, Kok NFM, Woensdregt K, Lambregts DMJ, et al. Diffusion-weighted MRI assessment of the peritoneal cancer index before cytoreductive surgery. Br J Surg. 2019;106(4):491-8. https://doi.org/10.1002/bjs.10989
Gadelhak B, Tawfik AM, Saleh GA, Batouty NM, Sobh DM, Hamdy O, et al. Extended abdominopelvic MRI versus CT at the time of adnexal mass characterization for assessing radiologic peritoneal cancer index (PCI) prior to cytoreductive surgery. Abdom Radiol (NY). 2019;44(6):2254-61. https://doi.org/10.1007/s00261-019-01939-y
Valle M, Garofalo A. Laparoscopic staging of peritoneal surface malignancies. Eur J Surg Oncol. 2006;32(6):625-7. https://doi.org/10.1016/j.ejso.2006.03.015
Sugarbaker PH. Laparoscopy in the diagnosis and treatment of peritoneal metastases. Ann Laparosc Endosc Surg. 2019;(4):42-42. https://doi.org/10.21037/ales.2019.04.04
Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol Suppl. 1999;4)(Suppl 3):S15-25. https://doi.org/10.1007/s002800051093
Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010;116(24):5608-18. https://doi.org/10.1002/cncr.25356
Coccolini F, Catena F, Glehen O, Yonemura Y, Sugarbaker PH, Piso P, et al. Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(7):911-9. https://doi.org/10.1016/j.ejso.2015.03.231
Otero JM, Arias F, Londoño E, Mora M, Becerra H, Cortés N, et al. Peritonectomía radical y quimioterapia intraperitoneal: cinco años de experiencia en la Fundación Santa Fe de Bogotá (ONCOLGroup - estudio ATIA). Rev.Col.Hematol.Oncol [Internet]. 2013;2(1):22-33. https://doi.org/10.51643/RevColHemOnc
Gangi A, Shah R. The landmark series: Appendiceal primary peritoneal surface malignancy. Ann Surg Oncol. 2022;29(3):2056-68. https://doi.org/10.1245/s10434-021-10856-8
Bijelic L, Ramos I, Goeré D. The landmark series: Surgical treatment of colorectal cancer peritoneal metastases. Ann Surg Oncol. 2021;28(8):4140-50. https://doi.org/10.1245/s10434-021-10049-3
Sun BJ, Lee B. Review of regional therapies for gastric cancer with peritoneal metastases. Cancers (Basel). 2022;14(3):570. https://doi.org/10.3390/cancers14030570
Chen V, Jones M, Cohen L, Yang W, Bedi J, Mohan HM, et al. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in small bowel adenocarcinoma with peritoneal metastasis: a systematic review. Pleura Peritoneum. 2022;7(4):159-67. https://doi.org/10.1515/pp-2022-0121
Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum. 1998;41(1):75-80. https://doi.org/10.1007/BF02236899
Votanopoulos KI, Shen P, Skardal A, Levine EA. Peritoneal metastases from appendiceal cancer. Surg Oncol Clin N Am. 2018;27(3):551-61. https://doi.org/10.1016/j.soc.2018.02.007
Rufián-Andujar B, Valenzuela-Molina F, Rufián-Peña S, Casado-Adam Á, Sánchez-Hidalgo JM, Rodríguez-Ortiz L, et al. From the ronnett to the PSOGI classification system for pseudomyxoma peritonei: A validation study. Ann Surg Oncol. 2021;28(5):2819-27. https://doi.org/10.1245/s10434-020-09560-w
Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2010;36(5):456-62. https://doi.org/10.1016/j.ejso.2010.01.006
Choudry HA, Pai RK. Management of mucinous appendiceal tumors. Ann Surg Oncol. 2018;25(8):2135-44. https://doi.org/10.1245/s10434-018-6488-4
Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy vs systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737-43. https://doi.org/10.1200/JCO.2003.04.187
Levine EA, Stewart JH, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1.000 patients. J Am Coll Surg. 2014;218(4):573-85. https://doi.org/10.1016/j.jamcollsurg.2013.12.013
Moaven O, Votanopoulos KI, Shen P, Mansfield P, Bartlett DL, Russell G, et al. Health- related quality of life after cytoreductive surgery /HIPEC for mucinous appendiceal cancer: results of a multicenter randomized trial comparing oxaliplatin and mitomycin. Ann Surg Oncol. 2019;27(3):772-80. https://doi.org/10.1245/s10434-019-08064-6
Bryant J, Clegg AJ, Sidhu MK, Brodin H, Royle P, Davidson P. Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei. Br J Surg. 2005;92(2):153-8. https://doi.org/10.1002/bjs.4862
El Halabi H, Gushchin V, Francis J, Athas N, MacDonald R, Nieroda C, et al. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis. Ann Surg Oncol. 2012;19(1):110-4. https://doi.org/10.1245/s10434-011-1840-y
Klaver CE, Groenen H, Morton DG, Laurberg S, Bemelman WA, Tanis PJ, et al. Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines. Colorectal Dis. 2017;19(3):224-36. https://doi.org/10.1111/codi.13593
Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii1-9. https://doi.org/10.1093/annonc/mdu260
Pestieau SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. Dis Colon Rectum. 2000;43(10):1341-6. https://doi.org/10.1007/BF02236627
Elias D, Blot F, El Otmany A, Antoun S, Lasser P, Boige V, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001;92(1):71-6. https://doi.org/10.1002/1097-0142(20010701)92:1%3C71::aid-cncr1293%3E3.0.co;2-9
Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11(2):178-86. https://doi.org/10.1245/aso.2004.05.009
Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681-5. https://doi.org/10.1200/JCO.2008.19.7160
Yonemura Y, Canbay E, Ishibashi H. Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. Scientific World J. 2013:978394. https://doi.org/10.1155/2013/978394
Tonello M, Baratti D, Sammartino P, Di Giorgio A, Robella M, Sassaroli C, et al. Microsatellite and RAS/RAF mutational status as prognostic factors in colorectal peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2022;29(6):3405-17. https://doi.org/10.1245/s10434-021-11045-3
Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 2018;36(18_Suppl):3503. https://doi.org/10.1200/JCO.2018.36.18_suppl.LBA3503
Razenberg LG, van Gestel YR, de Hingh IH, Loosveld OJ, Vreugdenhil G, Beerepoot LV, et al. Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice. BMC Cancer. 2016;(16):110. https://doi.org/10.1186/s12885-016-2158-8
van Oudheusden TR, Lemmens VE, Braam HJ, van Ramshorst B, Meijerink J, te Velde EA, et al. Peritoneal metastases from small bowel cancer: Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands. Surgery. 2015;157(6):1023-7. https://doi.org/10.1016/j.surg.2015.01.021
Oliveros R, Navarrera LF. Diagnóstico, estadificación y tratamiento del cáncer gástrico en Colombia desde 2004 a 2008 (REGATE-Colombia). Rev Col Gastroenterol. 2012;27(4):269-74. Disponible en: http://www.scielo.org.co/pdf/rcg/v27n4/en_v27n4a03.pdf
Globocan. Colombia. Disponible en: https://gco.iarc.fr/today/data/factsheets/populations/170-colombia-fact-sheets.pdf
Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, et al. Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol. 2013;43(10):972-80. https://doi.org/10.1093/jjco/hyt114
Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III Study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991-7. https://doi.org/10.1200/JCO.2006.06.8429
Chang JS, Kim KH, Keum KC, Noh SH, Lim JS, Kim HS, et al. Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration. J Surg Oncol. 2016;114(7):859-64. https://doi.org/10.1002/jso.24405
Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: Final results of a phase III randomized clinical trial. Ann. Surg. Oncol. 2011;18(6):1575-81. https://doi.org/10.1245/s10434-011-1631-5
Rau B, Brandl A, Piso P, Pelz J, Busch P, Demtröder C, et al. Peritoneal metastasis in gastric cancer: Results from the German database. Gastric Cancer. 2020;23:11-22. https://doi.org/10.1007/s10120-019-00978-0
Rau B, Lang H, Königsrainer A, Gockel I, Rau H-G, Seeliger H, et al. The effect of hyperthermic intraperitoneal chemotherapy (HIPEC) upon cytoreductive surgery (CRS) in gastric cancer (GC) with synchronous peritoneal metastasis (PM): a randomized multicentre phase III trial (GASTRIPEC-I-trial). Ann Oncol. 2021;32:S1040. https://doi.org/10.1016/j.annonc.2021.08.1485
Desiderio J, Chao J, Melstrom L, Warner S, Tozzi F, Fong Y, et al. The 30-year experience A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur. J. Cancer. 2017;79:1-14. https://doi.org/10.1016/j.ejca.2017.03.030
Tsushima T, Taguri M, Honma Y, Takahashi H, Ueda S, Nishina T, et al. Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. Oncologist. 2012;17(9):1163-70. https://doi.org/10.1634/theoncologist.2012-0079
Sun Y, Shen P, Stewart JH, Russell GB, Levine EA. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. Am Surg. 2013;79(6):644-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/23711278/
Liu Y, Ishibashi H, Takeshita K, Mizumoto A, Hirano M, Sako S, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal dissemination from small bowel malignancy: Results from a single specialized center. Ann Surg Oncol. 2016;23(5):1625-31. https://doi.org/10.1245/s10434-015-5056-4
Liu Y, Yonemura Y, Levine EA, Glehen O, Goere D, Elias D, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal metastases from a small bowel adenocarcinoma: Multi-institutional experience. Ann Surg Oncol. 2018;25(5):1184-92. https://doi.org/10.1245/s10434-018-6369-x
Cómo citar
Descargas
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2023 Revista Colombiana de Cancerología
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Todos los derechos reservados.
